Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 10,739 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hematologic Clear all
Completed Phase 2 Interventional

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

NCT00195000
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Mylotarg, Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Not applicable Interventional

The Ambient Light Multiple Myeloma Study

NCT05737732
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Not applicable Interventional

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT

NCT04629430
View directory record Official record
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Hodgkin Lymphoma, Hodgkin Disease, Myelofibrosis, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Sickle Cell Disease, Mantle Cell Lymphoma
Interventions
Pre-biotic foods/drinks
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

NCT00002630
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, cyclophosphamide, melphalan, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 14, 2026, 2:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

NCT03573700
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Interventions
Cyclophosphamide, Fludarabine, Mesna, CliniMACS, CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Drug · Device · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Completed No phase listed Observational

Circulating microRNAs as Disease Markers in Pediatric Cancers

NCT01541800
View directory record Official record
Conditions
Leukemia, Lymphoma, Central Nervous System
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
3 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 1 Interventional

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03266692
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions
ACTR087, SEA-BCMA
Biological
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 1 Interventional Results available

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

NCT01034592
View directory record Official record
Conditions
Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Lenalidomide
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT00941928
View directory record Official record
Conditions
Leukemia, Pediatric Cancer
Interventions
Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Not applicable Interventional

Unrelated Donor Stem Cell Transplantation

NCT01364363
View directory record Official record
Conditions
Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Chronic Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Large Granulocytic Leukemia
Interventions
Allogeneic transplantation
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 1 Interventional

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

NCT04640987
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback
Biological · Device · Drug
Lead sponsor
Porteus, Matthew, MD
Other
Eligibility
1 Month to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Completed No phase listed Observational

Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias

NCT01144793
View directory record Official record
Conditions
Leukemia, Lymphocytic, Leukemia, Myeloid
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 14, 2026, 2:30 AM EDT
Completed No phase listed Observational

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

NCT00281814
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT07582172
View directory record Official record
Conditions
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate, Melphalan, Multigated Acquisition Scan, Palifermin, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Not listed Phase 2 Interventional

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

NCT00036712
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 1 Interventional

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

NCT07585136
View directory record Official record
Conditions
Bone Marrow Failure Syndrome
Interventions
Filgrastim, Plerixafor, Leukapheresis
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Not yet recruiting No phase listed Observational

PRAISE-IR Versus CIBMTR Controls

NCT07717164
View directory record Official record
Conditions
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Interventions
Not listed
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
1 Year to 66 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

NCT02706899
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
vadastuximab talirine, Azacitidine, Placebo (for 33A)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Gilbert, Arizona • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Early Phase 1 Interventional

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

NCT06313398
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Hemoglobinopathy
Interventions
Biotin-labeled red blood cells
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03787498
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions
PLX2853
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

NCT02329847
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Ibrutinib, Nivolumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

NCT00496873
View directory record Official record
Conditions
Lymphoma
Interventions
Cytoxan, Nipent, Rituxan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00079456
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
temsirolimus, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 14, 2026, 2:30 AM EDT